The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Bakhtiiarova K.Z.

Bashkirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Ufa

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Vlasov Ia.V.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Spirin N.N.

Kafedra nervnykh bolezneĭ i meditsinskoĭ genetiki s kursom neĭrokhirurgii Iaroslavskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Stoliarov I.D.

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Provision of alemtuzumab safety is one of the main components of pharmacovigilance

Authors:

Khachanova N.V., Bakhtiiarova K.Z., Boĭko A.N., Vlasov Ia.V., Davydovskaya M.V., Evdoshenko E.P., Zakharova M.N., Malkova N.A., Sivertseva S.A., Spirin N.N., Stoliarov I.D., Shmidt T.E., Khabirov F.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2): 82‑87

DOI: 10.17116/jnevro201811808282

Views: 640

Downloaded: 14

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Khachanova NV, Bakhtiiarova KZ, Boĭko AN, et al. . Provision of alemtuzumab safety is one of the main components of pharmacovigilance. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2):82‑87. (In Russ.)
https://doi.org/10.17116/jnevro201811808282

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Vali­dation of e-version of Russian-language expa­nded disa­bility status scale (EDSS) for patients with multiple scle­rosis in the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):9-16
The effe­ctiveness of tele-rehabilitation for patients with multiple scle­rosis during the COVID-19 pandemic in 2020—2021 was evaluated in this study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):75-81
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Opti­cal cohe­rence tomo­graphy in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(3):59-68
Questionnaires for arm function asse­ssment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42
Features of primary forms of headache in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73
Neurofilament light chain: a diagnostic pote­ntial for multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications. In the last 5 years, there have been several reports of severe, sometimes lethal, listeriosis infection in patients treated with alemtuzumab. This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy. In January 2018, a meeting of the expert Council was held, at which the clinical recommendations published in 2017 were revised and updated.

Keywords:

multiple sclerosis
listeriosis
alemtuzumab

Authors:

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Bakhtiiarova K.Z.

Bashkirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Ufa

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Vlasov Ia.V.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Spirin N.N.

Kafedra nervnykh bolezneĭ i meditsinskoĭ genetiki s kursom neĭrokhirurgii Iaroslavskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Stoliarov I.D.

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

List of references:

  1. Khachanova NV, Davydovskaya MV, Evdoshenko EP. Updated risk stratification and risk management plan for Natalizumab-associated progressive multifocal leukoencephalopathyed. RMJ. 2017;13:3-7. (In Russ.)
  2. Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis — report of two cases. Int J Mol Sci. 2015;16:14669-14676. https://doi.org/10.3390/ijms160714669
  3. Holmoy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab — a case for better preventive strategies. BMC Neurol. 2017;17:65-68. https://doi.org/10.1155/2014/358051
  4. Alifirova VM, Bisaga GN, Boyko AN, Bryukhov VV, Davydovskaya MV, Zakharova MN, Zakharova EV, Malkova NA. Popova EV, Sologub GN, Sivertseva SA, Troshina EA, Khachanova NV, Schmidt TE. Clinical recommendations for the use of alemtuzumab (Lemtrada). J of Neurology and Psychiatry. 2017;117:2(2):115-126. (In Russ.) https://doi.org/10.17116/jnevro201711722115-126
  5. Coles A, Robertson N, Al-Araji A, Waller B, Brenner B, Mclean B, Gran B, Giovannoni G, Price S, Rashid W. Guidance on prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis. https://www.theabn.org/media/Guidance%20on%20the%20prevention%20of%20Listeria%20infection%20after%20alemtuzumab%20treatment%20of%20multiple%20sclerosis.pdf
  6. Yushchuk ND, Karetkina GN, Klimov EA, Boytsov PV, Kelly EI, Malyshev NA, Mandzhiev GD, Revazyan NR, Serobyan AG, Solovyeva LJ, Sheberstov NB. Listeriosis of pregnancy: the role of infectious disease in the diagnosis and treatment. Topical issues of infectious pathology. 6th Congress of infectious diseases of the Republic of Belarus. 29—30 may 2014, Vitebsk, Republic of Belarus. (In Russ.)
  7. Tartakovsky IS. Listeria: role in human infectious pathology and laboratory diagnostics. Clinical Microbiology and antimicrobial chemotherapy. 2000;2(2):20-30. (In Russ.)
  8. Hernandez-Milian A, Payeras-Cifre A. What is new in listeriosis? Biomed Res Int. 2014;358051. https://doi.org/10.1155/2014/358051
  9. Maertens De NC, Devleesschauwer B., Angulo F.J. et al. The global burden of listeriosis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;11:1073-1082. https://doi.org/10.1016/S1473-3099(14)70870-9
  10. Luchshev VI, Nikiforov VV, Burova SV, Tomilin YuN, Novikova LV, Pavlova AYu. Listeriosis. Medical case. 2005;2:71-76. (In Russ.)
  11. Nikolich-Zugich J, Li G, Uhrlaub JL, Renkema KR, Smithey MJ. Age-related changes in CD8 T cell homeostasis and immunity to infection. Semin Immunol. 2012;24:356-364. https://doi.org/10.1016/j.smim.2012.04.009
  12. Vazquez-Boland JA, Kuhn M, Berche P, Chakraborty T, Domínguez-Bernal G, Goebel W, González-Zorn B, Wehland J, Kreft J. Listeria pathogenesis and molecular virulence determinants. Clin Microbiol Rev. 2001;14:584-640. https://doi.org/10.1128/CMR.14.3.584-640.2001
  13. Zenewicz LA, Shen H. Innate and adaptive immune responses to Listeria monocytogenes: A short overview. Microbes Infect Inst Pasteur. 2007;9:1208-1215. https://doi.org/10.1016/j.micinf.2007.05.008
  14. Disson O, Lecuit M. Targeting of the central nervous system by Listeria monocytogenes. Virulence. 2012;3:213-221. https://doi.org/10.4161/viru.19586
  15. Drevets DA, Bronze MS. Listeria monocytogenes: Epidemiology, human disease, and mechanisms of brain invasion. FEMS Immunol. Med Microbiol. 2008;53:151-165. https://doi.org/10.1111/j.1574-695X.2008.00404.x
  16. Karetkina GN. Listeriosis. Attending physician. 2008;9:31-35. (In Russ.)
  17. Dekonenko EP, Kupriyanova LV, Golovatenco-Abramov KV. Listeriosny meningitis and its complications. Neurological journal. 2001;2:23-26. (In Russ.)
  18. Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmiere K. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Pract Neurol. 2016;16:389-393. https://doi.org/10.1136/practneurol-2015-001355
  19. WHO (2014) Essential Medicines and Health Products: Pharmacovigilance. World Health Organization. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.